FILING BY "EXPRESS MAIL

EV67811479245

Express Mail Label Number

Form PTO-1390-MOD U. S (REV 10-96)	Department of Commerce Patent and Trademark Office	ATTORNEY'S DOCKET NUMBER 33439-US-PCT							
TRANSMITTAL LETTER TO	U.S. APPLICATION NO. (If known, see 37 CFR 1.5)								
DESIGNATED/ELECTED O	10/57/17/								
CONCERNING A FILING U	10/576176								
INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED							
PCT/EP2004/012082	26 October 2004 (26.10.04)	27 October 2003 (27.10.03)							
TITLE OF INVENTION									
INDOLYL-PYRROLEDIONE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL AND VASCULAR									
DISORDERS RELATED TO BETA-AMYLOID GENERATION AND/OR AGGREGATION									
APPLICANT(S) FOR DO/EO/US									
AUBERSON ET AL.									

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. A copy of the International Application as filed (35 U.S.C. 371(c)(2)) 5. is transmitted herewith (required only if not transmitted by the International Bureau). has been transmitted by the International Bureau. (See Form PCT/IB/308) is not required, as the application was filed in the United States Receiving Office (RO/US). A translation of the International Application into English (35 U.S.C. 371(c)(2)). Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C.371(c)(3)). are transmitted herewith (required only if not transmitted by the International Bureau). have been transmitted by the International Bureau. have not been made; however, the time limit for making such amendments has NOT expired. have not been made and will not be made. A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)). An executed Declaration and Power of Attorney (original or copy) (35 U.S.C. 371(c)(4)). A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11. to 16. below concern document(s) or information included. 11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. A FIRST preliminary amendment. A SECOND or SUBSEQUENT preliminary amendment.

14.	\boxtimes	An Application Data Sheet under 37 CFR 1.76.
15.		A substitute specification.
16.		A change of power of attorney and/or address letter.
17.		A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821-1.825.
18.		A second copy of the published International Application under 35 U.S.C. 154(d)(4).
19.		A second copy of the English language translation of the International application under 35 U.S.C. 154(d)(4).
20.	\boxtimes	Other items or information: Unsigned Declaration

IAP20 Rec's FSTATTO 19 APR 2006

	CATION NO. (if known, see 37 CFR 1.5) INTERNATIONAL APPLICATION NO. ATTORNEY'S DO 33439-US-I PCT/EP2004/012082 ATTORNEY'S DO 33439-US-I											
The following fees are submitted:								CALCULATIONS PTO USE				
										ONLY		
21. 🛭 Basi	c nationa	al fee				· · · · · ·			\$300			
22. Examination Fee												
					report was prepared Article 33(1)-(4)				\$			
•									\$200			
. All 0	illei Silua	1110115		• • • •					Ψ200			
23. Search fee												
☐ If Se	arch fee	(37 CFR 1.4	l45(a)(2)) Las an Int	has l	been paid on the intitional Searching Aut	ernation	al		\$			
If Int	ernation	al Search Re	eport was	prep	ared and provided to	the Off	ice		\$400			
☐ All of	ther situa	ations	• • • • • • •	• • • •					\$			
			TOTA	L OF	21, 22 AND 23 =					\$	900	
Additional fee fo	r specifi	cation and d	rawings fi	iled in	paper over 100 she	ets (exc	luding	seque	nce listing	or compu	ter	
program listing thereof.	nled in a	n electronic i	medium).	The	fee is \$250 for each	additio	nai 50	sneets	of paper of	rraction		
Total Sheets	Extra	sheets			ch additional 50 or fi			RA	TE			
21 - 100 =	0	/50 =	thereof (i	rouna	up to a whole num 0	ber)	+x	\$	250	\$	~	
0	20 6 6-				otics lates then	7 20						
Surcharge of \$1 months from the		claimed price	ority date	(37 C] 30				\$		
CLAIMS		NUMBE	R FILED		NUMBER EXTR			RATE		•		
Total claims Independent cla	ims	15 2) =	0			<u>\$</u> \$	50 200	\$		
MULTIPLE DEF								\$	360	\$		
					TOTAL OF AB					\$	900	
			ntity, if ap	plicat	ole. Verified Small E	Intity Sta	temen	nt must	also be	\$	•	
filed (Note 37 CFR 1.9, 1.27, 1.28).								OTAL =	\$	900		
					anslation later than	□ 30	month	s from	the			
earliest claimed	priority	date (37 CFF	1.492(1)).	Т	ΌΤΔΙ	ΝΔΤ	ΙΟΝΔ	L FEE =	\$ \$	900	
Fee for recording	g the en	closed assig	nment (3	7 CFI	R 1.21(h)). The ass							
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property +							+	\$ \$	900			
TOTAL FEES ENCLOSED =								<u> </u>				
									be: ref	unt to unded	\$	
									ch	arged	\$	
a. A chec	k in the	amount of \$_	*		to cover the abo	ve fees i	s encl	osed.	•			
										fees. A		
c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-0134 in the name of Novartis.												
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.												
Send all correspondence to the address associated with Customer No. 001095, which is currently:												
Lydia 1. McNally							0		_			
Novartis Attorney for Applicants Corporate Intellectual Property Reg. No. 36,214												
One Health Plaza, Building 104 (862) 778-7898 East Hanover, NJ 07936-1080												
Last He	11104EI, I	10 07 000-10	••									